Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R H T Koornstra

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Breast (Edinburgh, Scotland)|October 3, 2015
St. Gallen endocrine response classes predict recurrence rates over timeR H T Koornstra, K J Beelen, A D Vincent, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 20, 2013
Panitumumab monotherapy as a second-line treatment in metastasised colorectal cancer: a single centre experienceI E G van Hellemond, G J Creemers, L J C van Warmerdam, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 11, 2009
Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometryS F Teunissen, H Rosing, R H T Koornstra, et al.
Nederlands Tijdschrift Voor Geneeskunde|May 25, 2017
W J B Blox, P D Gobardhan, T Rozema, et al.
The Journal of Pathology|November 11, 2008
Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancerC Holm, M Kok, R Michalides, et al.
Breast Cancer Research and Treatment|June 6, 2013
CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatmentK Beelen, M Opdam, T M Severson, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 23, 2018
Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapyM Bloemendal, M J A Rietveld, W W van Willigen, et al.
European Journal of Cancer (Oxford, England : 1990)|February 18, 2014
Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signatureC A Drukker, H C van den Hout, G S Sonke, et al.
ESMO Open|March 7, 2024
Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancerL W de Boo, K Jóźwiak, N D Ter Hoeve, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Breast (Edinburgh, Scotland)|October 3, 2015
St. Gallen endocrine response classes predict recurrence rates over timeR H T Koornstra, K J Beelen, A D Vincent, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 20, 2013
Panitumumab monotherapy as a second-line treatment in metastasised colorectal cancer: a single centre experienceI E G van Hellemond, G J Creemers, L J C van Warmerdam, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 11, 2009
Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometryS F Teunissen, H Rosing, R H T Koornstra, et al.
Nederlands Tijdschrift Voor Geneeskunde|May 25, 2017
W J B Blox, P D Gobardhan, T Rozema, et al.
The Journal of Pathology|November 11, 2008
Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancerC Holm, M Kok, R Michalides, et al.
Breast Cancer Research and Treatment|June 6, 2013
CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatmentK Beelen, M Opdam, T M Severson, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 23, 2018
Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapyM Bloemendal, M J A Rietveld, W W van Willigen, et al.
European Journal of Cancer (Oxford, England : 1990)|February 18, 2014
Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signatureC A Drukker, H C van den Hout, G S Sonke, et al.
ESMO Open|March 7, 2024
Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancerL W de Boo, K Jóźwiak, N D Ter Hoeve, et al.
Pageof 1